# Tempus AI, Inc.

Type: Company (TEM)

Source: GetYourBrief — https://getyourbrief.com/entity/tempus-ai-inc
Canonical HTML page: https://getyourbrief.com/entity/tempus-ai-inc

## Recent coverage (6 stories, network-wide)

### FDA Clears Tempus ECG-PH, Targeting PH That Affects 10% of Adults 65+
2026-08-25 00:45:00 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2

Tempus AI announced FDA 510(k) clearance for Tempus ECG-PH, an AI-enabled tool that analyzes standard 12-lead ECGs for pulmonary hypertension signs. The device targets symptomatic adults 40 and older, aiming to address underdiagnosis without invasive procedures.
Full story: https://gethealthbrief.com/story/tempus-ecg-ph-fda-clearance-health-it

### Tempus Scores 3rd FDA AI Clearance: ECG-PH Flags PH Risk in 12-Lead ECGs
2026-08-25 00:44:50 · Sector: ai · Sentiment: Positive · Impact: 7/10 · Sources: 2

Tempus's ECG-PH AI model analyzes raw 12-lead ECG waveforms for binary signs associated with elevated mPAP >20 mmHg, receiving FDA 510(k) clearance and marking the company's third cardiovascular AI device. This matters for ML teams as regulatory acceptance of diagnostic AI broadens.
Full story: https://getaibrief.com/story/tempus-ecg-ph-third-fda-ai-clearance

### Kadensa Capital Trims Tempus AI Stake Amid Institutional Divergence
2026-03-17 01:33:52 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Kadensa Capital Ltd reduced its position in Tempus AI (TEM) by 4.8% during the third quarter, signaling a tactical adjustment by the institutional investor. This move comes as the precision medicine firm sees high volatility and divergent sentiment among major funds, including aggressive buying from ARK Invest.
Full story: https://getfinancebrief.com/story/kadensa-capital-tempus-ai-stake-reduction

### Cathie Wood Doubles Down on AI: ARK Invest Buys $2M of Tempus AI Amid Slump
2026-03-16 00:34:29 · Sector: ai · Sentiment: Neutral · Impact: 5/10 · Sources: 3

ARK Invest CEO Cathie Wood has increased her position in Tempus AI with a $2 million purchase, signaling continued conviction in AI-driven healthcare despite a 15% year-to-date decline. This move comes as Wood's flagship ARKK fund faces renewed pressure, trailing the S&P 500 significantly over a five-year horizon.
Full story: https://getaibrief.com/story/cathie-wood-ark-invest-tempus-ai-purchase

### Cathie Wood Doubles Down on AI with $2M Tempus AI Buy Amid Market Slump
2026-03-16 00:33:20 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 3

ARK Invest CEO Cathie Wood has increased her stake in Tempus AI with a $2 million purchase, signaling continued conviction in high-growth technology despite a 15% year-to-date decline for the stock. This move comes as her flagship Ark Innovation ETF struggles to keep pace with the broader market, currently trailing the S&P 500 as Wood maintains her stance that the AI sector is far from a bubble.
Full story: https://getfinancebrief.com/story/cathie-wood-ark-tempus-ai-investment-analysis

### ARK Invest Doubles Down on Tempus AI Amid Precision Medicine Volatility
2026-03-16 00:32:42 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Cathie Wood's ARK Investment Management has purchased $2 million worth of Tempus AI shares, reinforcing its position in the precision medicine firm despite a 15% year-to-date decline. The move underscores Wood's commitment to 'coiled spring' AI and biotech assets, even as her flagship funds face significant performance headwinds compared to the broader market.
Full story: https://getbiobrief.com/story/ark-invest-tempus-ai-purchase-precision-medicine

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.